C. diff – Art24-1-001 StudyRPadmin2021-04-20T14:47:08+00:00
Prevent C. diff from Returning
Did you know even when successfully treated, C. diff recurrence is common? Up to 25% of people with C. diff will get infected again. A study at the Louisiana Research Center is recruiting individuals who are currently being treated for C. diff. infection. You may be eligible to enroll and receive compensation.
About the study:
The primary purpose of the ART24-01-001 study is to see how the investigational study drug, compared with placebo, is tolerated in patients who recently had a Clostridium difficile infection (CDI), and how well the study drug, compared with placebo, may help to prevent future recurrent episodes of CDI.
The experimental drug to be tested in this study is composed of a “gut-friendly” bacteria commonly found in the environment and in fermented or other foods such as miso, soybean paste, or fermented rice or locust bean-derived products which acts against the bacteria Clostridium difficile.
All study-related visits, tests, and study medications will be provided to participants at no cost by the biopharmaceutical company sponsoring this clinical trial.
To be eligible for the ART24-1-001 study, study participates must:
Be 18-75 years of age
Have experienced a recent Clostridium difficile infection (primary or recurrent infection) and completed a standard of care course of Clostridium difficile infection antibiotics (vancomycin, fidaxomicin or metronidazole administered for 10 to 21 days) within 3 to 7 days of study enrollment,
Have achieved clinical cure for that episode of Clostridium difficile infection based on signs and symptoms
How Do I Get Involved
If you feel you are interested in participating in the ART24-1-001 clinical study, please call (318) 525-3233. A study coordinator will determine if the trial is right for you.